The results showed that the proportion of patients with a partial response or better was 33% (14 of 43; 90% CI 21-47) in the phase 2 study, suggesting mTOR inhibitors have the potential role in combination with bortezomib for the treatment of relapsed and refractory MM patients (58). The gene discussed is MTOR; the disease is Miyoshi myopathy.